Kornitzer Capital Management Inc. KS Sells 31,000 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Kornitzer Capital Management Inc. KS lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 31.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 66,262 shares of the medical research company's stock after selling 31,000 shares during the quarter. Kornitzer Capital Management Inc. KS's holdings in IQVIA were worth $13,021,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC increased its position in shares of IQVIA by 710.1% in the fourth quarter. Venturi Wealth Management LLC now owns 1,361 shares of the medical research company's stock valued at $267,000 after acquiring an additional 1,193 shares during the period. Sanctuary Advisors LLC raised its position in IQVIA by 17.1% during the 4th quarter. Sanctuary Advisors LLC now owns 6,437 shares of the medical research company's stock valued at $1,299,000 after purchasing an additional 939 shares during the last quarter. Copperleaf Capital LLC grew its position in shares of IQVIA by 8.2% in the 4th quarter. Copperleaf Capital LLC now owns 8,704 shares of the medical research company's stock worth $1,710,000 after buying an additional 662 shares during the last quarter. Principal Securities Inc. increased its stake in shares of IQVIA by 7.4% during the fourth quarter. Principal Securities Inc. now owns 29,696 shares of the medical research company's stock valued at $5,836,000 after buying an additional 2,047 shares during the period. Finally, Hickory Asset Management Inc. purchased a new stake in IQVIA in the fourth quarter worth $941,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IQVIA

In related news, Director John G. Danhakl bought 1,275 shares of the company's stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

IQV has been the subject of several research reports. Morgan Stanley increased their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Robert W. Baird cut their price target on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They issued an "overweight" rating and a $250.00 price objective for the company. Leerink Partners restated an "outperform" rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, TD Cowen decreased their target price on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $251.22.

IQVIA Price Performance

Shares of NYSE IQV traded down $1.49 during mid-day trading on Friday, reaching $192.52. The company's stock had a trading volume of 274,253 shares, compared to its average volume of 1,369,168. The stock has a fifty day moving average of $199.73 and a two-hundred day moving average of $216.79. The firm has a market capitalization of $33.90 billion, a PE ratio of 25.69, a P/E/G ratio of 2.01 and a beta of 1.48. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.86 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.